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Abstract
Objective—Squamous cell carcinoma (SCC) of the rectum is rare, but as with anal cancer, risk 
may be increased among immunosuppressed individuals. We assessed risk of rectal SCC in HIV-
infected people.
Design—Population-based registry
Methods—We utilized the HIV/AIDS Cancer Match, a linkage of US HIV and cancer registries 
(1991–2010), to ascertain cases of anal SCC, rectal SCC, rectal non-SCC, and colon non-SCC. We 
compared risk in HIV-infected persons to the general population using standardized incidence 
ratios (SIRs) and evaluated risk factors using Poisson regression. We reviewed cancer registry 
case notes to confirm site and histology for a subset of cases.
Results—HIV-infected persons had an excess risk of rectal SCC compared to the general 
population (SIR=28.9; 95%CI 23.2–35.6), similar to the increase for anal SCC (SIR=37.3). Excess 
rectal SCC risk was most pronounced among HIV-infected men who have sex with men (MSM, 
SIR=61.2). Risk was not elevated for rectal non-SCC (SIR=0.88) or colon non-SCC (SIR=0.63). 
Individuals diagnosed with AIDS had higher rectal SCC rates than those with HIV-only (incidence 
rate ratio=1.86; 95%CI 1.04–3.31). Based on available information, one-third of rectal SCCs were 
determined to be misclassified anal cancer.
Conclusions—HIV-infected individuals, especially with advanced immunosuppression, appear 
to have substantially elevated risk for rectal SCC. As for anal SCC, rectal SCC risk was highest in 
MSM, pointing to involvement of a sexually transmitted infection such as human papillomavirus. 
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Site misclassification was present, and detailed information on tumor location is needed to prove 
that rectal SCC is a distinct entity.
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INTRODUCTION
Colorectal cancer is a major cause of morbidity and mortality, with 132,700 incident cases 
and 49,700 deaths estimated for the US in 2015 [1]. The vast majority of colorectal cancer 
cases are adenocarcinomas [2]. In contrast, squamous cell carcinoma (SCC) in the 
colorectum is extremely rare. In the US, SCCs comprise only 1–2% of diagnosed rectal 
tumors with an annual incidence of 1.54 per 1,000,000 person-years in males and 3.00 per 
1,000,000 person-years for females. [3]
Because of the rarity of rectal SCC, little is known about its etiology. To date, there are 
fewer than 100 published case reports since the first case described in 1919 [4–13]. Human 
papillomavirus (HPV) has been proposed as an etiologic agent for rectal SCC because of the 
proximity of the rectum to the anus and the known role of HPV in anal SCC, but results of 
HPV testing in rectal SCC tumors have been conflicting [7,9–12]. Reports published since 
2000 often note the co-occurrence of ulcerative colitis [4, 8, 10, 11], pointing to 
inflammation as another possible co-factor. Although the rectum does not normally contain 
squamous epithelium, tumors might theoretically originate from areas of squamous 
metaplasia arising in the presence of inflammatory damage. The occurrence of such rectal 
squamous metaplasia has been documented in patients with ulcerative colitis, including a 
report of rectal squamous metaplasia occurring 7 years prior to the diagnosis of rectal SCC. 
[11, 14]
Two of the most recent case reports have described rectal SCC occurring in HIV-infected 
males [9, 12]. In preliminary data generated for a study describing cancer trends in HIV-
infected people [15], we noted that approximately 30% of rectal cancers in HIV-infected 
persons were SCCs (unpublished observations). This high proportion, relative to the 1–2% 
observed in the general population, suggests that progressive immunodeficiency caused by 
HIV infection (i.e., acquired immunodeficiency syndrome [AIDS]) may be an unidentified 
risk factor for rectal SCC. Although HIV-infected people do not have an increased risk of 
colorectal cancer overall [16, 17], prior studies have not specifically examined the 
association with rectal SCC. Notably, HIV-infected persons have a strongly increased risk of 
anal cancer [16–18], and there may be etiologic similarity between rectal SCC and anal 
cancer (which is primarily also a SCC). However, because of the overall rarity of rectal SCC 
and the contiguous location of the rectum and the anal canal, there may also be site 
misclassification of anal SCC as rectal SCC.
In light of these possibilities, the objective of our study was to quantify the risk of rectal 
SCC in HIV-infected persons, both overall and within the group most likely to have anal 
HPV infection (i.e., men who have sex with men [MSM]). We used data from the HIV/
AIDS Cancer Match (HACM) Study (http://hivmatch.cancer.gov/) [19], a linkage of HIV 
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and cancer registries, which provided information on cancer for a large population-based 
sample of HIV-infected people. We explored the possibility that rectal SCC may represent 
misclassified anal cancer through the examination of case notes collected by cancer 
registries. In addition, we estimated the risk of rectal SCC in solid organ transplant 
recipients, another immunosuppressed population, using data from the Transplant Match 
Study.
METHODS
The present study used data from HIV registries in the HACM Study that provided data on 
people registered with HIV infection with and without a prior AIDS diagnosis: Colorado, 
Connecticut, Florida, Georgia, Michigan, New Jersey, and Texas. We included cancers from 
cancer registries diagnosed during: (1) years when HIV infection and AIDS diagnoses were 
both reported to HIV registries and (2) years when cancer registries had completed 
ascertainment of cases at the time of the data linkage. Included registries (years of cancer 
diagnosis) were therefore: Colorado (1991–2007), Connecticut (2002–2010), Florida (1998–
2002), Georgia (2004–2008), Michigan (1992–2010), New Jersey (1992–2007), and Texas 
(1997–2009).
We assessed rectal cancer (International Classification of Diseases for Oncology version 3 
[ICD-O3] topography code C209) and, for comparison, colon cancer (ICD-O3 codes C180–
189 or C260) and anal cancer (ICD-O3 codes C210–212 or C218). We further classified 
cases based upon their histological diagnosis, either as SCC or non-SCC. The following 
ICD-O-3 histology codes provided by the cancer registries were used to define SCC status: 
8052, 8070, 8071, 8072, 8073, 8074, 8075, 8076, 8077, 8078, 8083, and 8084. The 
remaining histologies were classified as non-SCC, excluding Kaposi sarcoma, lymphoma, 
mesothelioma, and poorly specified subtypes. The specific histologies classified as non-SCC 
among the identified HIV-infected cases and in the general population are included in 
Supplemental Table 1. We define outcomes as anal SCC, rectal SCC, rectal non-SCC, and 
colon non-SCC and consider only the first diagnosis for each cancer outcome.
We calculated standardized incidence ratios (SIRs) to compare cancer risk in HIV-infected 
people to risk in the general population, comprised almost entirely of HIV-uninfected 
individuals. SIRs are defined as the number of observed cases divided by the number 
expected based on general population rates (standardized to the HIV population by age, sex, 
race/ethnicity, calendar year, and cancer registry). We estimated SIRs overall and separately 
based on sex and HIV risk category (MSM, non-MSM male injection drug user [IDU], male 
heterosexual, female IDU, female heterosexual, other/unknown). We further used Poisson 
regression to estimate rectal SCC rates and assess potential risk factors for rectal SCC 
among HIV-infected people, including sex and HIV risk category, attained age, race/
ethnicity, and degree of immunosuppression (prior AIDS diagnosis vs. no AIDS [i.e., HIV-
only]). Follow-up for cancer diagnoses among the HIV-infected individuals accrued from 
the earliest of HIV report, AIDS diagnosis, or beginning of cancer registration. Follow-up 
ended at the earliest of death or end of cancer registration.
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To examine potential misclassification of the cancer outcomes, we requested de-identified 
case notes from 4 of the participating registries (Colorado, Michigan, New Jersey, and 
Texas) on a proportion of anal and rectal cancer cases from HIV-infected people (i.e., cancer 
registry cases that matched to a record in the HIV registry), sampled according to the 
reported histology (SCC, non-SCC), as well as a comparison set of HIV-uninfected cases 
(i.e., cancer registry cases that did not match to the HIV registry). One cancer registrar, one 
HIV clinician, and two cancer epidemiologists (AC, EE, MS, and RR) independently 
reviewed the case notes for each individual and assigned a location (anus, rectum) and 
histology to the tumor. Reviewers utilized the available information on biopsy and tumor 
location as well as treatment administration to determine the most likely location. Detailed 
pathology reports and supporting medical records beyond the summary provided by the 
cancer registries were not available. Reviewers were blinded to the HIV status and risk 
category.
For any case that the reviewer classified as rectal SCC, a level of confidence was noted on a 
scale from 1–5 (1=very uncertain, 2=somewhat uncertain, 3=more likely than not, 
4=somewhat certain, 5=very certain). Scores ≥4 were considered to indicate high confidence 
based on the amount of supporting information (e.g., rectum consistently listed as location in 
both diagnosis and treatment notes), and scores <4 were assigned to cases with little 
supporting data (e.g., rectum SCC listed but no supporting diagnostic or treatment notes). 
Rectal SCC cases with no conflicting information or information specifically pointing to an 
anal cancer diagnosis remained classified as rectal SCC cases. Any disagreements in the 
classification assigned between the 4 reviewers were resolved by consensus. According to 
patient HIV status, we report both: (1) the proportion of all reviewed cases in our sample for 
which either site or histology was reassigned by consensus and (2) the proportion of 
reviewed rectal SCC cases that were classified as such with ‘high confidence’ by at least one 
reviewer.
To determine whether misclassification could account for the excess of rectal SCC in HIV-
infected persons, we recalculated the SIR using the results of the case review under two 
conditions. First, after estimating the proportion p1 of reviewed rectal SCC cases that were 
potentially misclassified, we recalculated the SIR using only the remaining proportion of the 
observed rectal SCC cases (1-p1). Secondly, we recalculated the SIR after removing the 
proportion of cases p2 that were not scored as high confidence by at least one independent 
reviewer.
To further explore the potential association between immunosuppression and rectal SCC, we 
examined rectal SCC risk in solid organ transplant recipients (OTRs). OTRs are 
administered immunosuppressive medications to prevent graft rejection and represent a 
patient population with distinct risk factors from HIV-infected persons but who also 
experience immunosuppression. We evaluated the risk of rectal SCC in solid organ 
transplant recipients using data from the Transplant Cancer Match (TCM) Study. The TCM 
Study is designed similarly to the HACM Study, linking data from the U.S. transplant 
registry to multiple cancer registries (http://transplantmatch.cancer.gov/).[20] We calculated 
SIRs comparing the number of cancers occurring after transplant to the expected number 
based on general population rates.
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We identified 295,738 HIV-infected people in these seven states, of whom 1,189 were 
diagnosed with anal cancer (64.4%), rectal cancer (18.8%), or colon cancer (16.7%). 
Notably, 89 (39.7%) of 224 HIV-infected cases of rectal cancer had a histological diagnosis 
of SCC, compared to only 1.3% of 209,775 HIV-uninfected rectal cases from these same 
states. For anal cancer, 92.0% of cases among HIV-infected people were SCCs in contrast to 
only 1.0% of HIV-infected colon cancer cases.
The incidence of rectal SCC cases in HIV-infected persons (5.61 per 100,000 person-years) 
substantially exceeded the rate in the general population (SIR = 28.9, 95% CI 23.2–35.6). 
(Table 1) Risk was elevated in both males and females, and for several HIV risk groups, 
although the excess was most marked in HIV-infected MSM (SIR = 61.2; 95% CI 47.8–
77.2), with 79.8% of observed cases occurring in this group and an incidence equal to 10.2 
per 100,000 person-years. This pattern was very similar to that observed for anal SCC 
(overall SIR= 37.3; 95% CI 34.6–40.2; MSM SIR= 65.6; 95% CI 60.2–71.5), with 75.0% of 
identified anal SCCs occurring in HIV-infected MSM. In contrast, incidence in HIV-
infected persons was not elevated relative to the general population for rectal non-SCC 
(SIR=0.88; 95% CI 0.74–1.04) and was actually reduced for colon non-SCC (SIR=0.63; 
95% CI 0.55–0.73). Similarly, in our analysis of immunosuppressed transplant recipients, 
we observed that the risk of rectal SCC exceeded that in the general population (SIR = 3.46, 
95% CI 1.66–6.36, N=10 cases), whereas the risk of rectal non-SCC in transplant recipients 
was reduced (SIR=0.61; 95% CI 0.51–0.72, N=146 cases).
Among HIV-infected people, incidence of rectal SCC was higher in MSM compared to 
other HIV-infected groups (incidence rate ratio [IRR]=3.44; 95% CI 1.96–6.03), (Table 2). 
Persons ≥30 years of age had a higher risk for rectal SCC than those <30 years of age, as did 
whites compared to non-whites, although neither association was significant after 
multivariable adjustment. The incidence of rectal SCC did not appreciably change over time 
during the HAART era. Finally, people diagnosed with AIDS had higher rectal SCC 
incidence than those with HIV-only (IRR=1.92; 95% CI 1.08–3.42).
To explore the possibility that some rectal SCCs were misclassified anal cancers, we 
reviewed the case abstracts for 113 cases from four cancer registries, including 73 rectal 
SCC cases (55 HIV-infected, 18 HIV-uninfected). Examples of the information available on 
these cases along with some brief comments are given in Table 3. The level of detail varied, 
ranging from only a simple statement of the diagnosis to information on locations of 
biopsies and treatment received. For certain cases, information on the location of the tumor 
mass in different parts of the abstract was conflicting and often indicated that the tumor 
spanned the anorectal region; we classified these tumors as anal cancers because the site 
code for ‘anorectal lesion’ (C218) is classified as anal cancer [http://apps.who.int/
classifications/icd10/]. Approximately one third of rectal SCC cases were determined to be 
potentially misclassified anal SCCs (HIV-infected cases: 34.5%, 95%CI 23.4–47.7%; HIV-
uninfected cases: 33.3%, 95%CI 16.3–56.3%), (Table 4). After removal of these cases, the 
majority of cases assigned as rectal SCC by the consensus of reviewers were scored with 
‘high confidence’ by at least one reviewer (58.3%, 95%CI 42.2%–72.9%).
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Applying the same rectal SCC misclassification proportion (34.5%) in our sample of 55 
HIV-infected cases with available case notes to all 89 HIV-infected rectal SCC cases in the 
HACM Study would result in the removal of 31 misclassified tumors, leaving 58 remaining 
rectal SCCs. Using this corrected approximation of the observed rectal SCCs in HIV-
infected persons, the SIR would remain elevated (SIR=18.8; 95% CI 14.3–24.3). 
Furthermore, if we count only the proportion of rectal SCCs that were assigned as ‘high 
confidence’ (58.3%), leaving 34 remaining cases, there would still be a substantial excess of 
rectal SCC (SIR=11.0; 95% CI 7.64–15.4). Each of these revised SIR estimates is 
conservative because no misclassification of rectal SCCs among the HIV-uninfected general 
population was assumed (i.e., we did not change the expected rate in the denominator). For 
example, approximately 3 rectal SCC cases were expected based on counts observed in the 
general population. However, if one-third of the general population cases were misclassified 
anal SCC, then the observed count in HIV-infected persons (i.e., 89 cases) should have been 
divided by 2 rather than 3, which would have generated an ever more pronounced SIR for 
rectal SCC.
The level of detail for these more probable HIV-infected rectal SCCs varied in quality as 
well (Supplemental Table 2). Among the 21 ‘high confidence’ cases, certain treatment 
details were provided for 11, with combination radiotherapy and chemotherapy most often 
listed. Specific location of the tumor within the rectum (i.e., proximal or distal rectum) was 
mostly missing, with the exception of case 21b, which was described as a tumor at 6–12cm 
from the anal verge. Advanced tumors may be more likely to span the anorectal region and 
be misclassified. Although detailed information on tumor size was not available, the stage 
distribution among this set of 21 cases did not appear to be heavily skewed towards 
advanced disease (11 local tumors, 4 regional tumors, 1 distant tumor, 5 unknown).
DISCUSSION
This is the first report to demonstrate that HIV-infected people have a markedly elevated 
risk for rectal SCC. This excess risk was most pronounced in HIV-infected MSM, a risk 
pattern very similar to that observed for anal SCC, which is caused by HPV. Notably, risk 
estimates for rectal SCC differed from those for rectal non-squamous rectal tumors and 
colon cancer. We eliminated obvious misclassification of anal SCC as rectal SCC. Some 
misclassification may have remained, but the extent to which this was the explanation for 
the excess incidence associated with HIV infection could not be determined without detailed 
information on tumor location.
Very little is known about risk factors for developing rectal SCC due to its rarity. Meta-
analyses of studies of cancer risk in HIV-infected people show no consistent evidence of 
increased colorectal cancer risk, but these studies combined both colon and rectal cancers 
and did not separate histologic subtypes [16, 21]. The absence of an elevated risk is not 
surprising because, as we observed in this study, most colorectal cancers in HIV-infected 
people are still non-SCCs. Interestingly, the failure to evaluate colon and rectal tumors as 
distinct in prior studies may have also precluded the ability to observe a deficit of colon 
cancer in HIV-infected persons, as documented here.
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In support of a role for immunosuppression as a risk factor for rectal SCC, we found a 
higher risk in HIV-infected people who had progressed to AIDS than in HIV-infected people 
who had not. In addition, we report here that rectal SCC risk was elevated among transplant 
recipients, another immunosuppressed patient population. Prior studies of transplant 
recipients have demonstrated a modest increase in colorectal cancer overall [20, 21] but the 
evaluation of all colorectal cancers together likely missed the stronger association specific to 
rectal SCC.
Given the anatomic continuity of the anal canal and the rectum, it is relevant to consider the 
etiology of anal cancer. Anal cancer is caused by infection with HPV-16 or, to a lesser 
extent, other oncogenic subtypes of HPV [22]. HIV-infected persons have an elevated risk 
of developing anal cancer [16–18], and long-term immunosuppression is a risk factor for 
anal cancer among HIV-infected individuals [23, 24]. Our data further confirm previous 
observations that MSM have a particularly increased risk of anal neoplasia [23, 25]. This 
high risk is largely due to a high prevalence of receptive anal sex practices, which increases 
the chance of HPV acquisition [26, 27].
In our study, the patterns for rectal SCC mirrored those for anal SCC, suggesting HPV 
infection could also be a contributing cause of rectal SCC. Specifically, HIV-infected MSM 
had the greatest elevation in rectal SCC risk. The elevation for rectal SCC was smaller in 
transplant recipients who, although immunosuppressed, may be less likely than HIV-
infected MSM to have anal HPV infection. In addition, US population trends in anal and 
rectal SCC incidence have recently been reported to be similar, [3] providing further 
evidence that SCC etiology may be similar across the anorectal region. Prior studies have 
documented HPV DNA positivity in some rectal SCC tumors, as well as the presence of 
either HPV oncoprotein transcripts or altered levels of HPV-targeted tumor suppressor 
proteins [11–13]. However, these reports are limited to less than 10 cases, and two other 
studies using different assays, including in situ hybridization, reported negative results for 
the presence of HPV [8, 10].
Our observation of a strong association between HIV and rectal cancer specific to SCC 
histology may have been due in large part to misclassification of anal SCCs as rectal SCCs. 
The rectal and anal regions are continuous, and large tumors can span both regions, making 
them difficult to distinguish. Our greatest challenge was the limited data available in the 
cancer registries to assess the diagnoses. To some extent, the uncertainty is unavoidable, as 
there is inherent clinical ambiguity. It was reassuring that the rectal SCC cases that appeared 
to be misclassified anal cancers were equally present in both HIV-infected persons and the 
general population, pointing to non-differential misclassification. When we removed the 
cases that were probable anal cancers from the HIV-infected rectal SCC group, a nearly 20-
fold excess risk of rectal SCC remained. Furthermore, we calculate that nearly 90% of the 
89 rectal SCC cases reported in HIV-infected persons would have to have been 
misclassified, leaving fewer than 8 cases, to leave no excess risk compared to the general 
population (i.e., SIR ≤1). On the other hand, because rectal SCCs are not common, any 
misclassification would not substantially affect the SIRs for anal cancer. For instance, even 
if all of these 89 observed rectal SCCs were in fact anal SCCs, the SIR for anal SCC would 
only increase from 38 to 42. Future work requires a greater level of detail on tumor size and 
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location within the rectum, with demonstration of the presence of small, proximal SCCs of 
the rectum needed to conclusively prove that rectal SCC is a distinct entity from anal SCC.
Strengths of our registry-based study include a large enough HIV population to gather an 
adequate number of cancers classified by both tumor site and histology. This proved crucial 
for documenting previously unappreciated associations, which were masked by examination 
of colorectal cancer or rectal cancer overall. Our design also allowed us to compare across 
tumor sites, providing support for a similar etiology between rectal and anal SCC. Also 
unique to this study was access to cancer registry case notes, which allowed us to assess the 
potential misclassification of cancer sites. Limitations must also be noted, including a lack 
of conclusive details for some tumors due to factors such as clinical ambiguity and poor 
documentation. We also lacked data on HIV treatment and CD4 T-cell counts, which 
prevented more detailed examination of the role of immunosuppression. We did not have 
access to tumor tissues, which would have allowed us to test directly the hypothesis that 
HPV is etiologically relevant for rectal SCC as a distinct entity in the context of HIV 
infection.
We have shown that HIV-infected individuals are at an elevated risk of developing rectal 
SCC. The increased risk of rectal SCC among HIV-infected people occurred in a pattern 
very similar to anal cancer (i.e., particularly high in MSM), suggesting a sexually 
transmitted infectious etiology such as HPV. We also documented higher risk in people with 
AIDS than in other HIV-infected people, as well as elevated risk in transplant recipients, 
pointing to a role for immunosuppression. Although we observed ambiguity and 
misclassification between anal SCC and rectal SCC that could account for a proportion of 
the excess rectal SCC risk observed, the results are also consistent with squamous tumors 
with shared etiology (i.e., likely HPV) arising not only in the anal canal but also the rectum 
and occurring most frequently among HIV-infected MSM.
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